REVELATION BIOSCIENCES, INC.
REVBWNasdaq
$0.01
0.0%Jul 17 close · end-of-day
Price
1Y↓ -23.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$32,077.20
Enterprise Value
-$14.1M
P/E
—
P/S
—
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-76.0%
ROIC
—
Debt / Equity
—
Net Cash
$14.1M
Return 1Y
-21.9%
Company profile
Revelation Biosciences, Inc. focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti-viral nasal drop for the prevention or treatment of respiratory viral infections.
- CEO
- James M. Rolke
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- revbiosciences.com
Management & directors
- Rolke JamesChief Executive Officer
- Zygmont Chester Stanley IiiChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
REVBW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$2.71↓ -89.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | -$12.0M | -$10.9M | -$8.7M | -$8.0M | -$9.1M |
| Net income | -$1.6M | -$12.0M | -$10.8M | -$120,254.00 | -$15.0M | -$8.9M |
| Diluted EPS | — | -$42.50 | -$149.20 | -$8.44 | -$1,052.16 | -$23.95 |
| Operating cash flow | -$216,664.00 | -$11.1M | -$11.2M | -$7.3M | -$18.3M | -$8.3M |
| Free cash flow | — | -$11.2M | — | — | -$18.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.5M | -$1.8M | -$1.8M | -$2.1M | -$2.5M | -$1.9M | -$2.6M | -$3.1M |
| Net income | -$8.4M | -$2.2M | -$1.7M | -$2.1M | -$2.4M | -$1.9M | -$2.5M | -$3.0M |
| Diluted EPS | -$246.27 | -$40.15 | -$726.37 | -$25.34 | -$7.01 | -$1.77 | $10.17 | -$2.71 |
| Operating cash flow | -$2.5M | -$9.3M | -$3.7M | -$2.8M | -$1.9M | -$1.6M | -$2.0M | -$3.2M |
| Free cash flow | -$2.5M | -$9.3M | -$3.8M | — | — | — | — | -$3.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 10, 2026
Jun 1, 2026
May 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-30 | Zygmont Chester Stanley III· Chief Financial Officer | Tax withholding | 13,285 | $1.10 | $14,613.50 | filing |
| 2026-04-30 | Rolke James· Chief Executive Officer | Tax withholding | 10,115 | $1.13 | $11,429.95 | filing |
| 2026-02-04 | Zygmont Chester Stanley III· Chief Financial Officer | Tax withholding | 13,100 | $1.65 | $21,615.00 | filing |
| 2026-02-03 | Rolke James· Chief Executive Officer | Tax withholding | 8,521 | $1.86 | $15,849.06 | filing |
| 2026-02-03 | Chawla Lakhmir S | Tax withholding | 2,261 | $1.85 | $4,182.85 | filing |
| 2026-02-03 | CARVER JENNIFER | Tax withholding | 1,661 | $1.87 | $3,106.07 | filing |
| 2026-02-03 | ROPER JESS | Tax withholding | 1,591 | $1.85 | $2,943.35 | filing |
| 2026-01-08 | Rolke James· Chief Executive Officer | Award | 532,829 | $0.90 | $479,546.10 | filing |
| 2026-01-08 | Zygmont Chester Stanley III· Chief Financial Officer | Award | 78,145 | $0.90 | $70,330.50 | filing |
| 2026-01-08 | CARVER JENNIFER | Award | 41,981 | $0.90 | $37,782.90 | filing |
| 2026-01-08 | ROPER JESS | Award | 41,981 | $0.90 | $37,782.90 | filing |
| 2026-01-08 | Chawla Lakhmir S | Award | 41,981 | $0.90 | $37,782.90 | filing |
| 2025-10-29 | Rolke James· Chief Executive Officer | Award | 390,614 | $1.28 | $499,985.92 | filing |
| 2025-10-29 | Zygmont Chester Stanley III· Chief Financial Officer | Award | 390,614 | $1.28 | $499,985.92 | filing |
| 2025-10-29 | CARVER JENNIFER | Award | 15,625 | $1.28 | $20,000.00 | filing |
| 2025-10-29 | ROPER JESS | Award | 15,625 | $1.28 | $20,000.00 | filing |
| 2025-10-29 | Chawla Lakhmir S | Award | 15,625 | $1.28 | $20,000.00 | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.